Chugai

Overview

Japanese pharmaceutical company that co-developed emicizumab (Hemlibra) with Roche, a bispecific antibody replacing factor VIII cofactor function in hemophilia A and B, with $5.4B in annual sales as of 2025. Chugai and Roche co-developed emicizumab (Hemlibra), a bispecific antibody that bridges factor IX and factor X with micromolar binding affinity to each arm, mimicking factor VIII cofactor activity without involving factor VIII, thus working in inhibitor patients. Emicizumab generated $5.4 billion in sales in the year prior to the talk, reflecting very wide adoption across hemophilia A patients globally. (Hemophilia Treatment Innovations (05:00-10:00))